ClinicalTrials.gg
CompletedNCT05769595Updated Mar 14, 2025Results posted

Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)

A Phase 1 interventional study of MK-2060 and Placebo in End-Stage Renal Disease (ESRD), End-Stage Kidney Disease (ESKD) and Kidney Failure, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed at 12 sites in Japan. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Kidney Failure, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Merck & Co., Inc.

Enrollment
7th of 12
17 · median 18
Started
2023
with 1 other
Phase 1
10 of 12
none open now
Registered
10th of 12
by date

Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, this one is the 7th largest by enrollment, is one of 2 that started in 2023, is one of 10 in phase 1, and was the 10th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc is open now. The open studies under Kidney Failure, Chronic, anywhere →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of MK-2060 after a single dose intravenous (IV) administration in Japanese older participants with end stage renal disease (ESRD) on dialysis. There is no primary hypothesis for this study.

03

Conditions studied

  • End-Stage Renal Disease (ESRD)
  • End-Stage Kidney Disease (ESKD)
  • Kidney Failure, Chronic
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Japanese descent with all 2 biological parents of Japanese descent
  • On hemodialysis (HD) or hemodiafiltration (HDF) with single-pool Kt/V (spKt/V) ≥1.2, using arteriovenous (AV) fistula or AV graft ≥3 months prior to Screening 1 at a healthcare center, and is on the same dialysis regimen ≥2 weeks prior to Screening 1
  • Be judged to plan to continue or anticipate the use of the current AV fistula or AV graft until the poststudy visit

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • On peritoneal dialysis or other dialysis modalities except for HD and HDF
  • History of deep vein thrombosis or pulmonary embolism
  • History of vascular access thrombosis within 1 month prior to Screening 1
  • Personal or family history of bleeding disorder
  • History of GI bleeding, duodenal polyps or active gastroduodenal ulcer within 5 years prior to Screening 1, or history of severe hemorrhoidal bleed within 3 months prior to Screening 1
  • History of frequent epistaxis within 3 months prior to Screening 1 or active gingivitis
  • At the time of screening or predose, planned significant dental procedures, or other planned surgical procedures within duration of participation in the trial
  • History of receiving any human immunoglobulin preparation such as intravenous immunoglobulin (IVIG) or a brand of Rho(D) immune globulin (RhoGAM) within 1 year prior to Screening 1
  • History of receiving any biological therapy within 3 months prior to Screening 1, or vaccination within 1 month prior to the dose of study intervention
  • Requires or anticipates requiring the use of following prohibited medications until the poststudy visit: anticoagulants, antiplatelet medications and non-steroidal anti-inflammatory drugs (NSAIDs)
  • Participated in another study within 1 month prior to Screening 1
  • Has blood coagulation test ( [aPTT] or prothrombin time [PT]) above 1.2X (ULN) at Screening 1 from the central laboratory for safety
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    MK-2060

    Participants receive MK-2060 50 mg via a single intravenous (IV) infusion over 60-minutes.

    Biological: MK-2060

  • Placebo comparator
    Placebo

    Participants receive a single IV saline infusion over 60 minutes.

    Drug: Placebo

Interventions

  • BiologicalMK-2060

    Lyophilized powder diluted in normal saline for IV infusion

  • DrugPlacebo

    IV infusion

    Also known as: Normal saline

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The number of participants who experienced an AE is reported.

    Time frame: Up to approximately 164 days

  2. Number of Participants Who Discontinued Study Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The number of participants who discontinued study due to an AE is reported.

    Time frame: Up to approximately 164 days

Secondary outcomes

  1. Area Under the Concentration-Time Curve of MK-2060 From Time 0 to Infinity (AUC 0-inf)

    Blood samples were collected at specified intervals for the determination of AUC0-inf. AUC0-inf is defined as the area under the concentration-time curve of MK-2060 from time zero to infinity.

    Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis

  2. Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to Last (AUC0-last)

    Blood samples were collected at specified intervals for the determination of AUC0-last. AUC0-last is defined as the area under the plasma concentration-time curve from time zero to time of last measurable concentration of MK-2060.

    Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis

  3. Area Under the Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours Postdose (AUC0-168)

    Blood samples were collected at specified intervals for the determination of AUC0-168. AUC0-168 is defined as the area under the concentration-time curve of MK-2060 from time zero to 168 hours.

    Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis

  4. Maximum Concentration (Cmax) of MK-2060

    Blood samples were collected at specified intervals for the determination of Cmax. Cmax is defined as the maximum concentration of MK-2060 reached.

    Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis

  5. Concentration at 168 Hours (C168) Postdose of MK-2060

    Blood samples were collected at specified intervals for the determination of C168. C168 is defined as the maximum concentration of MK-2060 reached at 168 hours postdose.

    Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis

  6. Time to Maximum Concentration (Tmax) of MK-2060

    Blood samples were collected at specified intervals for the determination of Tmax. Tmax is defined as time to the maximum concentration of MK-2060 reached.

    Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis

  7. Time of the Last Measurable Plasma Concentration (Tlast) of MK-2060

    Blood samples were collected at specified intervals for the determination of Tlast. Tlast is defined as the time to the last measurable concentration of MK-2060 reached.

    Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis

  8. Terminal Half-Life (t ½) of MK-2060

    Blood samples were collected at specified intervals for the determination of t½. t½ is defined as the time required to divide the MK-2060 plasma concentration by two after reaching pseudo-equilibrium, following a single dose of MK-2060.

    Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis

  9. Clearance (CL) of MK-2060

    Blood samples were collected at specified intervals for the determination of CL. CL is the volume of plasma from which the study drug is completely removed per unit time.

    Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis

  10. Volume of Distribution (Vz) of MK-2060

    Blood samples were collected at specified intervals for the determination of Vz. Vz is the apparent volume of distribution during the terminal phase.

    Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis

  11. Change From Baseline in Activated Partial Thromboplastin Time (aPTT)

    Blood samples were collected for the determination of aPTT. Change from baseline in aPTT up to 168 hours post dose (pre dialysis) is reported.

    Time frame: Baseline and 168 hours post dose

07

Results

Posted Mar 14, 2025

Participant flow

Participant flow — Overall Study
MilestoneMK-2060Placebo
Started125
Completed125
Not completed00

Outcome measures

PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The number of participants who experienced an AE is reported.

Time frame:
Up to approximately 164 days
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsMK-2060Placebo
Number of Participants Who Experienced an Adverse Event (AE)104
PrimaryNumber of Participants Who Discontinued Study Due to an AE

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The number of participants who discontinued study due to an AE is reported.

Time frame:
Up to approximately 164 days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Due to an AE
ParticipantsMK-2060Placebo
Number of Participants Who Discontinued Study Due to an AE00
SecondaryArea Under the Concentration-Time Curve of MK-2060 From Time 0 to Infinity (AUC 0-inf)

Blood samples were collected at specified intervals for the determination of AUC0-inf. AUC0-inf is defined as the area under the concentration-time curve of MK-2060 from time zero to infinity.

Time frame:
Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Reported as:
Geometric mean · hours*nmol/L
Area Under the Concentration-Time Curve of MK-2060 From Time 0 to Infinity (AUC 0-inf)
hours*nmol/LMK-2060Placebo
Area Under the Concentration-Time Curve of MK-2060 From Time 0 to Infinity (AUC 0-inf)35000 ± 31.8—
SecondaryArea Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to Last (AUC0-last)

Blood samples were collected at specified intervals for the determination of AUC0-last. AUC0-last is defined as the area under the plasma concentration-time curve from time zero to time of last measurable concentration of MK-2060.

Time frame:
Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Reported as:
Geometric mean · hours*nmol/L
Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to Last (AUC0-last)
hours*nmol/LMK-2060Placebo
Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to Last (AUC0-last)34500 ± 31.8—
SecondaryArea Under the Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours Postdose (AUC0-168)

Blood samples were collected at specified intervals for the determination of AUC0-168. AUC0-168 is defined as the area under the concentration-time curve of MK-2060 from time zero to 168 hours.

Time frame:
Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Reported as:
Geometric mean · hours*nmol/L
Area Under the Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours Postdose (AUC0-168)
hours*nmol/LMK-2060Placebo
Area Under the Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours Postdose (AUC0-168)10100 ± 23.4—
SecondaryMaximum Concentration (Cmax) of MK-2060

Blood samples were collected at specified intervals for the determination of Cmax. Cmax is defined as the maximum concentration of MK-2060 reached.

Time frame:
Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Reported as:
Geometric mean · nmol/L
Maximum Concentration (Cmax) of MK-2060
nmol/LMK-2060Placebo
Maximum Concentration (Cmax) of MK-2060110 ± 26.0—
SecondaryConcentration at 168 Hours (C168) Postdose of MK-2060

Blood samples were collected at specified intervals for the determination of C168. C168 is defined as the maximum concentration of MK-2060 reached at 168 hours postdose.

Time frame:
Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Reported as:
Geometric mean · nmol/L
Concentration at 168 Hours (C168) Postdose of MK-2060
nmol/LMK-2060Placebo
Concentration at 168 Hours (C168) Postdose of MK-206039.0 ± 30.9—
SecondaryTime to Maximum Concentration (Tmax) of MK-2060

Blood samples were collected at specified intervals for the determination of Tmax. Tmax is defined as time to the maximum concentration of MK-2060 reached.

Time frame:
Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Reported as:
Median · hours
Time to Maximum Concentration (Tmax) of MK-2060
hoursMK-2060Placebo
Time to Maximum Concentration (Tmax) of MK-20601.03 (0.88 to 12.02)—
SecondaryTime of the Last Measurable Plasma Concentration (Tlast) of MK-2060

Blood samples were collected at specified intervals for the determination of Tlast. Tlast is defined as the time to the last measurable concentration of MK-2060 reached.

Time frame:
Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Reported as:
Median · hours
Time of the Last Measurable Plasma Concentration (Tlast) of MK-2060
hoursMK-2060Placebo
Time of the Last Measurable Plasma Concentration (Tlast) of MK-20603407.34 (2186.65 to 3695.18)—
SecondaryTerminal Half-Life (t ½) of MK-2060

Blood samples were collected at specified intervals for the determination of t½. t½ is defined as the time required to divide the MK-2060 plasma concentration by two after reaching pseudo-equilibrium, following a single dose of MK-2060.

Time frame:
Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Reported as:
Geometric mean · Days
Terminal Half-Life (t ½) of MK-2060
DaysMK-2060Placebo
Terminal Half-Life (t ½) of MK-206022.7 ± 18.2—
SecondaryClearance (CL) of MK-2060

Blood samples were collected at specified intervals for the determination of CL. CL is the volume of plasma from which the study drug is completely removed per unit time.

Time frame:
Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Reported as:
Geometric mean · Liters/hour
Clearance (CL) of MK-2060
Liters/hourMK-2060Placebo
Clearance (CL) of MK-20600.00964 ± 31.8—
SecondaryVolume of Distribution (Vz) of MK-2060

Blood samples were collected at specified intervals for the determination of Vz. Vz is the apparent volume of distribution during the terminal phase.

Time frame:
Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Reported as:
Geometric mean · Liters
Volume of Distribution (Vz) of MK-2060
LitersMK-2060Placebo
Volume of Distribution (Vz) of MK-20607.58 ± 28.5—
SecondaryChange From Baseline in Activated Partial Thromboplastin Time (aPTT)

Blood samples were collected for the determination of aPTT. Change from baseline in aPTT up to 168 hours post dose (pre dialysis) is reported.

Time frame:
Baseline and 168 hours post dose
Reported as:
Geometric mean · Fold-Change from baseline
Change From Baseline in Activated Partial Thromboplastin Time (aPTT)
Fold-Change from baselineMK-2060Placebo
Change From Baseline in Activated Partial Thromboplastin Time (aPTT)2.45 (2.27 to 2.63)0.97 (0.87 to 1.09)
Statistical analysis
  • MK-2060 vs Placebo · Geometric mean ratio: 2.51 · 90% CI 2.24 to 2.82Geometric mean ratio is MK-2060/placebo

Adverse events

Collected over Up to approximately 164 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-2060 50 mg0/12 (0%)3/12 (25%)9/12 (75%)
Placebo0/5 (0%)1/5 (20%)4/5 (80%)
Most frequent serious events
Most frequent serious events
EventMK-2060 50 mgPlacebo
Mechanical ileusGastrointestinal disorders0/121/5
Peripheral arterial occlusive diseaseVascular disorders0/121/5
Enteritis infectiousInfections and infestations1/120/5
Shunt occlusionInjury, poisoning and procedural complications1/120/5
Shunt stenosisInjury, poisoning and procedural complications1/120/5
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/120/5
Most frequent other events
Showing 10 of 27
Most frequent other events
EventMK-2060 50 mgPlacebo
DuodenitisGastrointestinal disorders0/121/5
Oedema peripheralGeneral disorders1/121/5
PyrexiaGeneral disorders0/121/5
NasopharyngitisInfections and infestations2/121/5
Immunisation reactionInjury, poisoning and procedural complications1/121/5
Ligament sprainInjury, poisoning and procedural complications0/121/5
Lumbar vertebral fractureInjury, poisoning and procedural complications0/121/5
HypoglycaemiaMetabolism and nutrition disorders0/121/5
Intraductal papillary mucinous neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/121/5
HaematuriaRenal and urinary disorders0/121/5

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MK-2060PlaceboTotal
Mean70.2 ± 7.266.2 ± 8.369.0 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)MK-2060PlaceboTotal
Female314
Male9413
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MK-2060PlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino12517
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MK-2060PlaceboTotal
American Indian or Alaska Native000
Asian12517
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

12 sites
  • Kasugai Municipal Hospital ( Site 1203)
    Kasugai, Aichi 486-8510, Japan
  • Chubu Rosai Hospital ( Site 1202)
    Nagoya, Aichi 455-8530, Japan
  • Kojunkai Daido Hospital ( Site 1207)
    Nagoya, Aichi 457-8511, Japan
  • Jomo Ohashi Clinic ( Site 1210)
    Maebashi, Gunma 371-0046, Japan
  • Ibaraki Prefectural Central Hospital ( Site 1211)
    Kasama, Ibaraki 309-1793, Japan
  • Shonan Kamakura General Hospital ( Site 1205)
    Kamakura, Kanagawa 247-8533, Japan
  • Matsumoto City Hospital ( Site 1209)
    Matsumoto, Nagano 390-1401, Japan
  • Keiaikai Nakamura Hospital ( Site 1213)
    Beppu, Oita 874-0937, Japan
  • Omi Fureai Hospital ( Site 1204)
    Kusatsu, Shiga 525-8585, Japan
  • Ikegami General Hospital ( Site 1206)
    Ota, Tokyo 146-8531, Japan
  • Japanese Red Cross Fukuoka Hospital ( Site 1214)
    Fukuoka, 815-8555, Japan
  • Yamagata Tokushukai Hospital ( Site 1201)
    Yamagata, 990-0834, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Feb 2024, 8 months.

Results were first posted in Mar 2025, 1 year after primary completion.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 8 months is above that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2023
First posted
Mar 15, 2023
StartActual
Jun 14, 2023
Primary completionActual
Feb 15, 2024
CompletionActual
Feb 15, 2024
Results first posted
Mar 14, 2025
Last update
Mar 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05769595
Responsible party
Sponsor
First posted
Mar 15, 2023
Start date
Jun 14, 2023
Primary completion
Feb 15, 2024
Completion
Feb 15, 2024
Results posted
Mar 14, 2025
Last update
Mar 14, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-2060

Start the discussion